Drug Action
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
PDF page 754
Loading InternPractice…
Drug reference
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
PDF page 754
Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with other antidiabetic drugs (including insulin) if existing treatment fails to achieve adequate glycaemic control ▶BY MOUTH ▶Adult: 5 mg once daily, for further information on use with other antidiabetic drugs—consult product literature
PDF page 754
DUE TO INTERACTIONS ▶Dose of concomitant sulfonylurea or insulin may need to be reduced.
PDF page 754
Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised that linagliptin (Trajenta ®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as monotherapy when both metformin and a sulfonylurea are inappropriate (January 2013), and in combination with metformin when addition of a sulfonylurea is inappropriate (December 2011).
PDF page 754
→Appendix 1: linagliptin
PDF page 754
▶Uncommon Cough. nasopharyngitis ▶Rare or very rare Angioedema. skin reactions ▶Frequency not known Pancreatitis SIDE-EFFECTS, FURTHER INFORMATION Discontinue if symptoms of acute pancreatitis occur such as persistent, severe abdominal pain.
PDF page 754
Avoid—no information available.
PDF page 754
Avoid—present in milk in animal studies.
PDF page 754
There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Trajenta (Boehringer Ingelheim Ltd) Linagliptin 5 mg Trajenta 5mg tablets | 28 tablet P £33.26 DT = £33.26 Combinations available: Empagliflozin with linagliptin, p. 745
PDF page 754
5 mg once daily, for further information on use
First-line fragment. Read the complete Indications and Dose section above.
PDF page 754